• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Apexigen Inc.

    8/23/23 8:57:34 AM ET
    $APGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGN alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39488
    Issuer: Apexigen, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 900 Industrial Road
    Suite C
    San Carlos CALIFORNIA 94070
    Telephone number: 646-643-6716
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock, warrants
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-08-23 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $APGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifshitz Law PLLC Announces Investigations of APGN, GNL, RTL, and BACK

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of APGN and Pyxis Oncology, Inc. Under the terms of the proposed merger, APGN shareholders will receive 0.1725 shares of Pyxis Oncology, Inc. common stock for each share of APGN common stock owned. Following the merger, pre-merger Apexigen shareholders are expected to own approximately 10% of the outstanding equity of the combined company. If you are an APGN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz

      6/3/23 8:17:00 PM ET
      $APGN
      $BACK
      $GNL
      $RTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
      Real Estate Investment Trusts
    • Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

      - Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) - - DDLPS expansion cohort enrolling to inform a potential Phase 3 registration trial - SAN CARLOS, Calif., June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab (sotiga), Ap

      6/3/23 8:00:00 AM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology to Acquire Apexigen

      Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ("Pyx

      5/24/23 6:45:00 AM ET
      $APGN
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APGN
    Financials

    Live finance-specific insights

    See more
    • Pyxis Oncology to Acquire Apexigen

      Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ("Pyx

      5/24/23 6:45:00 AM ET
      $APGN
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma

      -Patients with liposarcoma (LPS) demonstrated prolonged median PFS (mPFS) relative to historical controls treated with standard of care of doxorubicin- -Encouraging PFS data from the ongoing investigator sponsored trial in collaboration with Columbia University supports expansion of the LPS cohort to inform a potential phase 3 registration-enabling trial- -Apexigen to host investor call with sarcoma expert and principal investigator, Gary Schwartz, M.D. at Columbia University, today, November 14, at 8:00 a.m. ET- SAN CARLOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeu

      11/14/22 7:00:00 AM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APGN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Apexigen Inc.

      15-12G - Apexigen, Inc. (0001814140) (Filer)

      9/5/23 4:57:27 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Apexigen Inc.

      S-8 POS - Apexigen, Inc. (0001814140) (Filer)

      8/23/23 5:15:36 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apexigen Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Apexigen, Inc. (0001814140) (Filer)

      8/23/23 9:01:17 AM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Zabrowksi Dan

      4 - Apexigen, Inc. (0001814140) (Issuer)

      8/25/23 7:42:15 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Wertheimer Samuel P returned 146,383 shares to the company, closing all direct ownership in the company

      4 - Apexigen, Inc. (0001814140) (Issuer)

      8/25/23 7:39:47 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Smith Scott Andrew

      4 - Apexigen, Inc. (0001814140) (Issuer)

      8/25/23 7:37:02 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apexigen Inc. (Amendment)

      SC 13G/A - Apexigen, Inc. (0001814140) (Subject)

      2/13/23 4:10:55 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Apexigen Inc.

      SC 13G - Apexigen, Inc. (0001814140) (Subject)

      2/13/23 4:04:53 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apexigen Inc. (Amendment)

      SC 13G/A - Apexigen, Inc. (0001814140) (Subject)

      1/26/23 4:07:41 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care